# Filing Detail

Form 8-K - Current report:
SEC Accession No. 0001493152-25-010282
Filing Date
2025-03-14
Accepted
2025-03-14 10:25:08
Documents
18
Period of Report
2025-03-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 |  | form8-k.htm iXBRL | 8-K | 45448
2 |  | ex10-1.htm | EX-10.1 | 2725
3 |  | ex10-1_001.jpg | GRAPHIC | 467136
4 |  | ex10-1_002.jpg | GRAPHIC | 230659
5 |  | ex10-1_003.jpg | GRAPHIC | 133039
| Complete submission text file | 0001493152-25-010282.txt |  | 1417234

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL SCHEMA FILE | lixt-20250311.xsd | EX-101.SCH | 3785
7 | XBRL DEFINITION FILE | lixt-20250311_def.xml | EX-101.DEF | 30058
8 | XBRL LABEL FILE | lixt-20250311_lab.xml | EX-101.LAB | 36769
9 | XBRL PRESENTATION FILE | lixt-20250311_pre.xml | EX-101.PRE | 27081
20 | EXTRACTED XBRL INSTANCE DOCUMENT | form8-k_htm.xml | XML | 5790

Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

EIN.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39717 | Film No.: 25738156
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)